Plus Therapeutics, a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome (RNL) intermediate drug product.   The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturin...